3 active not recruiting, 1 not yet recruiting, 1 recruiting. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Active not recruiting 3, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Advanced Ovarian Cancer: new trials by email Literature Review of Advanced Ovarian Cancer trials Research Report on Advanced Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer AK104 - Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody) | Phase 3 | Recruiting | Anhui Provincial Hospital | 100 | 2025-03-11 | 2026-10-28 |
| Plasmodium Immunotherapy for Advanced Ovarian Cancer Plasmodium immunotherapy - Advanced Ovarian Cancer | Phase 2 / Phase 3 | Not yet recruiting | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | 30 | 2024-07-20 | 2024-07-22 |
| The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer Ropivacaine, Saline Solution - Advanced Ovarian Cancer | Phase 3 | Active not recruiting | Karolinska Institutet | 220 | 2020-08-27 | 2026-09-28 |
| Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients Bevacizumab, Durvalumab, Olaparib - Advanced Ovarian Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1407 | 2019-01-04 | 2026-07-07 |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. Olaparib 300mg tablets - Newly Diagnosed, Advanced Ovarian Cancer | Phase 3 | Active not recruiting | AstraZeneca | 450 | 2013-08-26 | 2025-12-10 |
Ovarian Neoplasms (2) · Malaria, Vivax (1) · Pathologic Complete Response (1)
Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms (2) · Neoplasms by Site (2) · Ovarian Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Disease Attributes (1)
olaparib (2) · Bevacizumab (1) · CP protocol (1) · Ropivacaine (1) · Saline Solution (1) · durvalumab (1)
AstraZeneca (2) · Anhui Provincial Hospital (1) · CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. (1) · Karolinska Institutet (1)
China (4) · Brazil (2) · Canada (2) · France (2) · Italy (2) · Japan (2) · Poland (2) · South Korea (2) · Spain (2) · United States (2) · Australia (1) · Austria (1) · Belgium (1) · Bulgaria (1) · Denmark (1)
Carol Aghajanian (1) · Guo Shuiqun, Ph.D., M.D. (1) · Philipp Harter (1) · Prof Kathleen Moore, MD (1) · Prof Paul DiSilvestro, MD (1) · Sahar Salehi, MD, PhD (1)
PMID 30345884, PMID 33862001, PMID 34715071, PMID 35170751, PMID 36082969, PMID 37185961, PMID 39572271, PMID 39695768, PMID 40652770, PMID 40772525, PMID 40856042
2017 (1)